Metabolomics Workbench : NIH Data Repository

MB Sample ID: SA271300

Local Sample ID:	R Control 2A-01_14_1_3231
Subject ID:	SU002808
Subject Type:	Human
Subject Species:	Homo sapiens
Taxonomy ID:	9606

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR002817
Treatment Summary:	The human non-small cell lung cancer cell line (A549) was purchased from AmericanType Culture Collection (ATCC) (Manassas, USA). A doxorubicin-resistant A549 (A549-R) cell line was generated in our laboratory (Drug Design and Discovery Research Group, Pharmacology Laboratory, Sharjah Institute for Medical Research, University of Sharjah). To develop resistant cells from the parental A549 cells (A549-P), A549-P cells were treated with a tenth of Dox's maximal inhibitory concentration (IC10). The surviving population of cells was cultured in a new flask and treated with a gradual increase of Dox concentration for 8 months. Maintenance of A549-R cells resistance was at a dose of 0.02 µg/ml of Dox. A549-P and A549-R cells were cultured in a Dulbecco's Modified Eagle Medium/ Nutrient Mixture F-12 (1:1) medium (DMEM/F-12) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. The cells were incubated in a humidified atmosphere of 5% CO2 at 37 ˚C.

Treatment ID:

TR002817

Treatment Summary:

The human non-small cell lung cancer cell line (A549) was purchased from AmericanType Culture Collection (ATCC) (Manassas, USA). A doxorubicin-resistant A549 (A549-R) cell line was generated in our laboratory (Drug Design and Discovery Research Group, Pharmacology Laboratory, Sharjah Institute for Medical Research, University of Sharjah). To develop resistant cells from the parental A549 cells (A549-P), A549-P cells were treated with a tenth of Dox's maximal inhibitory concentration (IC10). The surviving population of cells was cultured in a new flask and treated with a gradual increase of Dox concentration for 8 months. Maintenance of A549-R cells resistance was at a dose of 0.02 µg/ml of Dox. A549-P and A549-R cells were cultured in a Dulbecco's Modified Eagle Medium/ Nutrient Mixture F-12 (1:1) medium (DMEM/F-12) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. The cells were incubated in a humidified atmosphere of 5% CO2 at 37 ˚C.